Autopsy report · NCT03208712
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
Cause of deathSlow enrollment
“Low accrual”
Life of this trial
- Registered 4 months before it started.
- Ran for about 9 months before it stopped.
- 1 participant enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Early Phase 1
- Sponsor
- University of Michigan Rogel Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Urothelial Carcinoma
- Interventions
- Atezolizumab; Radium-223
- Participants
- 1
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.